Tyra Biosciences, Inc.
TYRA · XNASCIK 1863127fmd_0AG5THR3GP76HA6C8146C861Y0Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 7 | 21 | 43 | 63 | 80 | 103 |
| Total operating expenses | 9 | 26 | 59 | 80 | 104 | 133 |
| Operating income | (9) | (26) | (59) | (80) | (104) | (133) |
| Interest and investment income | – | – | – | 11 | 18 | 13 |
| Other non-operating income (expense) | (0) | (0) | 4 | 11 | 18 | 13 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (9) | (26) | (55) | (69) | (86) | (120) |